18F-FLT PET Imaging in Patients With Advanced Melanoma



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:October 10, 2016
End Date:April 30, 2019
Contact:Richard L Wahl, M.D.
Email:rwahl@wustl.edu
Phone:(314) 362-7100

Use our guide to learn which trials are right for you!

Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR

In the current study, advanced positron emission tomography/computed tomography (PET/CT) and
positron emission tomography/magnetic resonance (PET/MR) imaging methods will be used to
validate our hypothesis that melanoma patients receiving Dual-Immune Checkpoint Blockade
(DICB) therapy, who ultimately achieve clinical benefit, will have an increase, or "FLARE",
in tumor FLT and/or FDG uptake from baseline, as seen after cycle#1 of treatment, and that
after 2 cycles of treatment responders will have a decline in FLT and FDG uptake, in
comparison to the patients classified as "non-responders". In addition, alterations in tumor
apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging
(DW/MRI) will be evaluated, expecting after cycle#1: transient reductions in ADC due to
lymphocyte proliferation, increased cellularity and restriction of water movement in
responding patients, with these patients tumors having increased ADC at 2 cycles into therapy
associated with tumor necrosis. This study will evaluate rather early PET imaging with FLT
and FDG is a useful imaging biomarker of response to DICB.


Inclusion Criteria:

- Patients must have histologically or cytologically confirmed diagnosis of
unresectable, stage III or metastatic melanoma.

- Patients who are eligible to receive combined dual immune-checkpoint blockade therapy
with ipilimumab and nivolumab, per referring oncologist.

- Life expectancy ≥ 6 months.

- Disease that is measurable. This is defined as lesions measuring at least 10mm on
radiologic imaging.

- The Eastern Cooperative Oncology Group (ECOG) performance status of 1 or better

- Age ≥18 years.

- Normal organ and marrow function as defined below

- Aspartate aminotransferase (AST) (SGOT) or alanine aminotransferase (ALT) (SGPT)
≤2.5 × institutional upper limit of normal (≤5 x upper limit of normal for
patient with liver metastasis)

- Total bilirubin within 1.5 x institutional level of normal or direct bilirubin ≤
upper limit of normal (ULN) for patient with total bilirubin levels > 1.5 ULN)

- Hemoglobin ≥ 9.0g/dL or ≥5.6mmol/L

- Absolute neutrophil count ≥1000/mcL

- Platelets ≥ 75K/mcL

- Women of child-bearing potential must have a negative urinary or serum pregnancy test
within 7 days of baseline imaging.

Exclusion Criteria:

- Patient may not be receiving any other investigational agents

- Significant auto-immune disease requiring hospitalization within the past two years or
any history of life-threatening auto-immune disease

- Immunosuppressive therapy including systemic corticosteroids except for maintenance
dosing for adrenal insufficiency

- Known additional malignancy that is progressing or requires active treatment with the
exceptions of basal cell carcinoma of the skin, squamous cell carcinoma of the skin,
or in situ cervical cancer that has undergone potentially curative therapy.

- Active autoimmune disease or a syndrome that requires systemic steroids or
immunosuppressive agents with the exceptions of replacement dose steroids for adrenal
insufficiency, vitiligo, resolved childhood asthma/atopy, intermittent use of inhaled
steroids, local steroid injections, hypothyroidism stable on hormone replacement, and
Sjogren's syndrome

- Active tuberculosis

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, autoimmune diseases, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements

- Patients with a pacemaker, stainless steel aneurysm clip or any other magnetic
resonance (MR) contraindicated implant or foreign body would warrant exclusion from
this study. Pacemakers may be reprogrammed or turned off by the strong MRI magnetic
field. Radio-frequency (RF) fields in MR can also cause severe heating of pacemaker
lead tips. Steel aneurysm clips are prone to torque in the strong MR field which can
displace the clips and may damage the vessel, resulting in hemorrhage, and/or death.

- History of pneumonitis requiring hospitalization or systemic immune suppressive
therapy.

- Pregnant women are excluded from this study
We found this trial at
1
site
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Richard L Wahl, M.D.
Phone: 314-362-7100
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials